Kantoff PW - Search Results

1

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.

Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Ross RW, et al. Among authors: kantoff pw. Clin Cancer Res. 2005 Jul 15;11(14):5195-8. doi: 10.1158/1078-0432.CCR-05-0431. Clin Cancer Res. 2005. PMID: 16033836

2

Chemotherapy for muscle-infiltrating bladder cancer.

Scher HI, Kantoff PW. Scher HI, et al. Among authors: kantoff pw. Hematol Oncol Clin North Am. 1992 Feb;6(1):169-78. Hematol Oncol Clin North Am. 1992. PMID: 1556048 Review.

3

Chemotherapy for metastatic bladder cancer.

Kantoff PW, Scher HI. Kantoff PW, et al. Hematol Oncol Clin North Am. 1992 Feb;6(1):195-203. Hematol Oncol Clin North Am. 1992. PMID: 1556050 Review.

4

Detection of circulating tumor cells in men with localized prostate cancer.

Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al. Seiden MV, et al. Among authors: kantoff pw. J Clin Oncol. 1994 Dec;12(12):2634-9. doi: 10.1200/JCO.1994.12.12.2634. J Clin Oncol. 1994. PMID: 7527455

5

New agents in the therapy of hormone-refractory patients with prostate cancer.

Kantoff PW. Kantoff PW. Semin Oncol. 1995 Feb;22(1 Suppl 1):32-4. Semin Oncol. 1995. PMID: 7532323 Review. No abstract available.

6

14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate.

Kantoff PW, Block C, Letvak L, George M. Kantoff PW, et al. Am J Clin Oncol. 1993 Dec;16(6):489-91. doi: 10.1097/00000421-199312000-00005. Am J Clin Oncol. 1993. PMID: 8256762 Clinical Trial.

7

Two differentially expressed genes in normal human prostate tissue and in carcinoma.

Wang FL, Wang Y, Wong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW, Pardee AB. Wang FL, et al. Among authors: kantoff pw. Cancer Res. 1996 Aug 15;56(16):3634-7. Cancer Res. 1996. PMID: 8705997

8

The prostate specific antigen. Its use as a tumor marker for prostate cancer.

Kantoff PW, Talcott JA. Kantoff PW, et al. Hematol Oncol Clin North Am. 1994 Jun;8(3):555-72. Hematol Oncol Clin North Am. 1994. PMID: 8707772 Review.

9

Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma.

Kibel AS, Krithivas K, Shamel LB, Kantoff PW, DeWolf WC. Kibel AS, et al. Among authors: kantoff pw. Urology. 1996 Nov;48(5):741-6. doi: 10.1016/S0090-4295(96)00235-X. Urology. 1996. PMID: 8911518

10

Cancer and Leukemia Group B trials for advanced prostate cancer.

Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. Small EJ, et al. Among authors: kantoff pw. Semin Oncol. 1996 Dec;23(6 Suppl 14):28-31. Semin Oncol. 1996. PMID: 8996582 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

482 results

Search Page

Filters